Mr. Heidrich is an advisor to The Column Group. He has been in venture capital for over 29 years, principally at Mayfield where he is currently a Partner Emeritus. For more than two decades, he was a Managing Director in MF Funds IV-X. During his tenure, he co-managed Mayfield’s health care initiative and helped establish the firm’s renowned franchise in health care. He currently serves on the board of Cytokinetics (CYTK). In addition, he is also an advisor to Prospect Venture Partners. Grant Heidrich was the past President of the Western Association of Venture Capital and former member of the board of directors of the National Venture Capital Association. In 2009 he received the Lifetime Achievement Award from the National Venture Capital Association. Grant also served as Chairman of the Board of Tularik (TLRK) until it was acquired by Amgen (AMGN). During his venture career, he has been on the boards of more than 20 public and private companies. He received his BA from Stanford University in the Department of Human Biology, and his MBA from Columbia University.